Impact of bosentan on exercise capacity in adults after the Fontan procedure: A randomized controlled trial

European Journal of Heart Failure

Volumn 15, Issue 6, 2013, Pages 690-698

  Schuuring, Mark J ^a,b   Vis, Jeroen C ^a   Van Dijk, Arie P J ^c   Van Melle, Joost P ^d   Vliegen, Hubert W ^e   Pieper, Petronella G ^d   Sieswerda, Gertjan T ^f   De Bruin Bon, Rianne H A C M ^a   Mulder, Barbara J M ^a,b   Bouma, Berto J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Bosentan; Exercise capacity; Fontan

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BOSENTAN; DIURETIC AGENT;

ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DYSPNEA; EXERCISE; FEMALE; FONTAN PROCEDURE; HEADACHE; HEART OUTPUT; HEART VENTRICLE SIZE; HUMAN; LEUKOPENIA; MALE; MULTICENTER STUDY; NEW YORK HEART ASSOCIATION CLASS; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VENOUS OXYGEN TENSION;

BOSENTAN; EXERCISE CAPACITY; FONTAN;

ADOLESCENT; ADULT; ANTIHYPERTENSIVE AGENTS; CARDIAC OUTPUT; ECHOCARDIOGRAPHY; EXERCISE; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; FONTAN PROCEDURE; HEART DEFECTS, CONGENITAL; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878017417     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hft017     Document Type: Article

References (34)

1. Gewillig M, Brown SC, Eyskens B, Heying R, Ganame J, Budts W, La Gerche A, Gorenflo M. The Fontan circulation: who controls cardiac output? Interact Cardiovasc Thorac Surg 2010; 10: 428-433.
2. Goldberg DJ, French B, McBride MG, Marino BS, Mirarchi N, Hanna BD, Wernovsky G, Paridon SM, Rychik J. Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. Circulation 2011; 123: 1185-1193.
3. Engelfriet P, Boersma E, Oechslin E, Tijssen J, Gatzoulis MA, Thile'n U, Kaemmerer H, Moons P, Meijboom F, Popelová J, Laforest V, Hirsch R, Daliento L, Thaulow E, Mulder B. The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period. The Euro Heart Survey on adult congenital heart disease. Eur Heart J 2005; 26: 2325-2333.
4. Griffiths ER, Kaza AK, Wyler von Ballmoos MC, Loyola H, Valente AM, Blume ED, del Nido P. Evaluating failing Fontans for heart transplantation: predictors of death. Ann Thorac Surg 2009; 88: 558-563; discussion 563-564.
5. Inai K, Nakanishi T, Nakazawa M. Clinical correlation and prognostic predictive value of neurohumoral factors in patients late after the Fontan operation. Am Heart J 2005; 150: 588-594.
6. Galiè N, Beghetti M, Gatzoulis M, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M; Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger Syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114: 48-54.
7. Duffels MGJ, Vis JC, Van Loon RLE, Nieuwkerk PT, van Dijk AP, Hoendermis ES, de Bruin-Bon RH, Bouma BJ, Bresser P, Berger RM, Mulder BJ. Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down's syndrome. Am J Cardiol 2009; 103: 1309-1315.
8. Duffels MGJ, Van der Plas MN, Surie S, Winter MM, Bouma B, Groenink M, van Dijk AP, Hoendermis E, Berger RM, Bresser P, Mulder BJ. Bosentan in pulmonary arterial hypertension: a comparison between congenital heart disease and chronic pulmonary embolism. Neth Heart J 2009; 17: 334-338.
9. Kempny A, Dimopoulos K, Uebing A, Moceri P, Swan L, Gatzoulis MA, Diller GP. Reference values for exercise limitations among adults with congenital heart disease. Relation to activities of daily life - single centre experience and review of published data. Eur Heart J 2012; 33: 1386-1396.
10. Van der Velde ET, Vriend JWJ, Mannens MMAM, Uiterwaal CS, Brand R, Mulder BJ. CONCOR, an initiative towards a national registry and DNA-bank of patients with congenital heart disease in the Netherlands: rationale, design, and first results. Eur J Epidemiol 2005; 20: 549-557.
11. Duffels MGJ, Engelfriet PM, Berger RMF, van Loon RL, Hoendermis E, Vriend JW, van der Velde ET, Bresser P, Mulder BJ. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int J Cardiol 2007; 120: 198-204.
12. Weinberg PM. Morphology of single ventricle. Prog Pediatr Cardiol 2002; 16: 1-9.
13. Schuuring MJ, Vis JC, Duffels MG, Bouma BJ, Mulder BJ. Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan. Ther Clin Risk Manag 2010; 6: 359-366.
14. American Thoracic Society; American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003; 167: 211-277.
15. Beaver WL, Wasserman K, Whipp BJ. A new method for detecting anaerobic threshold by gas exchange. J Appl Physiol 1986; 60: 2020-2027.
16. Wendel-Vos GCW, Schuit AJ, Saris WHM, Kromhout D. Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activity. J Clin Epidemiol 2003; 56: 1163-1169.
17. Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, O'Brien WL, Bassett DR Jr, Schmitz KH, Emplaincourt PO, Jacobs DR Jr, Leon AS. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 2000; 32: S498-S504.
18. Lancellotti P, Tribouilloy C, Hagendorff A, Moura L, Popescu BA, Agricola E, Monin JL, Pierard LA, Badano L, Zamorano JL; European Association of Echocardiography. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 1: aortic and pulmonary regurgitation (native valve disease). Eur J Echocardiogr 2010; 11: 223-244.
19. Gentles TL, Mayer JE Jr, Gauvreau K, Newburger JW, Lock JE, Kupferschmid JP, Burnett J, Jonas RA, Castaneda AR, Wernovsky G. Fontan operation in five hundred consecutive patients: factors influencing early and late outcome. J Thorac Cardiovasc Surg 1997; 114: 376-391.
20. Giardini A, Balducci A, Specchia S, Gargiulo G, Bonvicini M, Picchio FM. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J 2008; 29: 1681-1687.
21. Giardini A, Hager A, Pace Napoleone C, Picchio FM. Natural history of exercise capacity after the Fontan operation: a longitudinal study. Ann Thorac Surg 2008; 85: 818-821.
22. Zellers TM, Driscoll DJ, Mottram CD, Puga FJ, Schaff HV, Danielson GK. Exercise tolerance and cardiorespiratory response to exercise before and after the Fontan operation. Mayo Clin Proc 1989; 64: 1489-1497.
23. Paridon SM, Mitchell PD, Colan SD, Williams RV, Blaufox A, Li JS, Margossian R, Mital S, Russell J, Rhodes J; Pediatric Heart Network Investigators. A crosssectional study of exercise performance during the first 2 decades of life after the Fontan operation. J Am Coll Cardiol 2008; 52: 99-107.
24. Durongpisitkul K, Driscoll DJ, Mahoney DW, Wollan PC, Mottram CD, Puga FJ, Danielson GK. Cardiorespiratory response to exercise after modified Fontan operation: determinants of performance. J Am Coll Cardiol 1997; 29: 785-790.
25. Muller J, Hess J, Hager A. Daily physical activity in adults with congenital heart disease is positively correlated with exercise capacity but not with quality of life. Clin Res Cardiol 2012; 101: 55-61.
26. Argiento P, Chesler N, Mulè M, D'Alto M, Bossone E, Unger P, Naeije R. Exercise stress echocardiography for the study of the pulmonary circulation. Eur Respir J 2010; 35: 1273-1278.
27. Beghetti M. Fontan and the pulmonary circulation: a potential role for new pulmonary hypertension therapies. Heart 2010; 96: 911-916.
28. Ovaert C, Thijs D, Dewolf D, Ottenkamp J, Dessy H, Moons P, Gewillig M, Mertens L. The effect of bosentan in patients with a failing Fontan circulation. Cardiol Young 2009; 19: 1-9.
29. Koch AME, Zink S, Singer H, Dittrich S. B-type natriuretic peptide levels in patients with functionally univentricular hearts after total cavopulmonary connection. Eur J Heart Fail 2008; 10: 60-62.
30. Cooper TJ, Guazzi M, Al-Mohammad A, Amir O, Bengal T, Cleland JG, Dickstein K. Sildenafil in Heart Failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design. Eur J Heart Fail 2013; 15: 119-122.
31. Behling A, Rohde LE, Colombo FC, Goldraich LA, Stein R, Clausell N. Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. J Card Fail 2008; 14: 189-197.
32. Khambadkone S, Li J, De Leval MR, Cullen S, Deanfield JE, Redington AN. Basal pulmonary vascular resistance and nitric oxide responsiveness late after Fontantype operation. Circulation 2003; 107: 3204-3208.
33. Cai J, Su Z, Shi Z, Zhou Y, Xu Z, Xu Z, Yang Y. Nitric oxide and milrinone: combined effect on pulmonary circulation after Fontan-type procedure: a prospective, randomized study. Ann Thorac Surg 2008; 86: 882-888.
34. Bowater SE, Weaver RA, Thorne SA, Clift PF. The safety and effects of bosentan in patients with a Fontan circulation. Congenit Heart Dis 2012; 7: 243-249.